论文部分内容阅读
目的探讨不同亚型的乳腺癌在TEC新辅助化疗方案下的治疗效果。方法按乳腺癌Luminal A型、Luminal B型、HER-2阳性型和基底型分为4组,各组35例,回顾性分析各组经TEC方案新辅助化疗后的疗效。结果四组患者诊断年龄、肿瘤大小、Ki-67、肿瘤分期、组织学分级和化疗前肿瘤血流分级均无统计学差异(P>0.05)。Luminal A型、Luminal B型、HER-2阳性型及基底型的临床有效率分别为48.57%、42.86%、71.43%和65.71%;病理有效率为71.43%、57.14%、85.71%和80.00%,HER-2阳性型和基底型乳腺癌在TEC方案下治疗效果优于Luminal A和Luminal B型(P<0.05)。结论 TEC新辅助化疗方案下HER-2阳性型及基底型乳腺癌患者疗效较好,其机制值得进一步研究。
Objective To investigate the therapeutic effects of different subtypes of breast cancer under the TEC neoadjuvant chemotherapy regimen. Methods According to Luminal A type, Luminal B type, HER-2 positive type and basal type, the patients were divided into 4 groups and 35 cases in each group. The therapeutic effects of neoadjuvant chemotherapy with TEC regimen were retrospectively analyzed. Results There was no significant difference in diagnostic age, tumor size, Ki-67, tumor stage, histological grade and tumor grade before chemotherapy in the four groups (P> 0.05). The clinical effective rates of Luminal A, Luminal B, HER-2 positive and basal type were 48.57%, 42.86%, 71.43% and 65.71% respectively. The pathological effective rates were 71.43%, 57.14%, 85.71% and 80.00% HER-2-positive and basal-type breast cancers performed better than Luminal A and Luminal B in the TEC regimen (P <0.05). Conclusion The efficacy of TEC neoadjuvant chemotherapy in patients with HER-2-positive and basal-type breast cancer is better, and its mechanism deserves further study.